Edgewise Therapeutics, Inc.
EWTX
$29.69
-$0.81-2.66%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.39M | 9.38M | 9.05M | 9.20M | 9.17M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.98M | 46.86M | 42.61M | 45.96M | 45.54M |
| Operating Income | -55.98M | -46.86M | -42.61M | -45.96M | -45.54M |
| Income Before Tax | -50.22M | -40.67M | -36.12M | -40.80M | -39.66M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -50.22M | -40.67M | -36.12M | -40.80M | -39.66M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -50.22M | -40.67M | -36.12M | -40.80M | -39.66M |
| EBIT | -55.98M | -46.86M | -42.61M | -45.96M | -45.54M |
| EBITDA | -55.45M | -46.34M | -42.09M | -45.45M | -44.96M |
| EPS Basic | -0.47 | -0.39 | -0.34 | -0.43 | -0.42 |
| Normalized Basic EPS | -0.30 | -0.24 | -0.22 | -0.27 | -0.26 |
| EPS Diluted | -0.47 | -0.39 | -0.34 | -0.43 | -0.42 |
| Normalized Diluted EPS | -0.30 | -0.24 | -0.22 | -0.27 | -0.26 |
| Average Basic Shares Outstanding | 106.01M | 105.49M | 104.94M | 95.13M | 94.72M |
| Average Diluted Shares Outstanding | 106.01M | 105.49M | 104.94M | 95.13M | 94.72M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |